Stock Ticker

  • Loading stock data...

Four Stocks To Watch: Twenty-First Century Fox Inc (FOXA), QUALCOMM Inc. (QCOM), DryShips Inc. (DRYS), Ariad Pharmaceuticals Inc. (ARIA)

Boston, MA 10/04/2014 (wallstreetpr) – Leonardo DiCaprio, who is currently acting in Twenty-First Century Fox Inc (NASDAQ:FOXA)‘s most awaited movie ‘ The Revenant,’ has decided to take a break from acting career for some time. He was slated to work in Walter Isaacson’s biography of Steve Jobs. It is currently learnt that DiCaprio has said […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Director Alexander Denner Acquires Shares Indirectly

Boston, MA 08/21/2114 (wallstreetpr) – A global oncology company, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Director Alexander Denner had resorted to buying the company shares from the open market indirectly on August 15. The acquisition of shares was done for Sarissa Capital for two of its funds. Interestingly, the move comes in the wake of a Sell […]

The Unseen Opportunity In Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Boston, MA 11/27/2013 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is not crippled by the suspension of its primary cancer therapy Iclusig in the U.S. A big of history about this is that regulatory authorities in the U.S. have raise red flag over the safety of Iclusig. The drug is believed to cause blood clots which can […]

EU Signals Green To Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s Iclusig

Boston, MA 11/25/2013 (wallstreetpr) – The biotech company Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)  finally breaths in air of ease as its blood cancer drug makes it through the European Union’s (EU) vote of confidence. On Friday, the stock soared as high as 35% easing out the intense pressure, the stock has been under for the past one […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s Shares Continue Downward Trend

Boston, MA 11/01/2013 (wallstreetpr) – American oncology major Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stocks continued their downward spiral with an upward 65 million shares transacted after recent legal developments around the company’s arraigned recent class action lawsuit filed by law firm Glancy Binkow & Goldberg LLP. Ariad stocks have been hurtling downward with intermittent buoyancy over the last […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Shares Sensitive To Leukemia Drug

Boston, MA 10/30/2013 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), in the first week of October reported a collapse of 59% at the stock market, following poor results of trails for its drug Iclusig. The company had been conducting trails for the drug that held great promise for long term myeloid leukemia patients. The ongoing trails […]

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) move to new office put on hold

Ariad Pharmaceuticals Inc., (NASDAQ:ARIA) which has seen a deep drop in its share value due to worries about the safety of its drug used to treat leukemia. The company has shelved its plans of moving into a headquarters and laboratory complex which is being built at Cambridge’s Kendall Square. The company spokesman Jeffrey Krasner said […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Picks After Huge Plunge

Boston, MA 10/22/2013 (wallstreetpr) – After plunging more than 40% Friday last week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a positive rally on Monday, gaining $10.11% to close up $2.94, but dropped 0.68 in the after hours. When the company abruptly announced termination of clinical trials on its leukemia drug, the stock exchange market reacted negatively to this […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Stops Further Trials Of Lclusig On Leukemia Patients

Boston, MA 10/18/2013 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it would stop a study it had undertaken as a first option for leukemia. The study involves the approved drug lclusig which it was treating as the first option for people suffering from leukemia. The company now fears a risk of clotting among patients on […]

Is Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) A Sinking Ship?

Boston, MA 10/16/2013 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) drug Iclusig is proving the some treatments are worse than the cure. Billed as a possible cure in the treatment of a rare form of blood cancer, the drug has so many severe side effects that the U.S. Food and Drug Administration (USFDA) have asked doctors and […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s Woes Deepen

Boston, MA 10/15/2013 (wallstreetpr) – What happens when a company with a single product faces disappointing setbacks in its research on that product? The product has shown tremendous potential and the management has been very quick to share any small good information with the general public. They have raised expectations to a very high level, […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) – Focus On Fresh Clinical Trial To Bring Drug Back In Market

Boston, MA 10/11/2013 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is a global oncology company focused on the development, discovery, and commercialization of medicines for cancer patients. Since the data showing the rising number of test patients who suffered from blood clots and increasing heart problems, the company has stopped enrolling any new patients in current trials […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s Cancer Drug On Hold

Boston, MA 10/11/2013 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has suffered a huge setback after the FDA put a partial hold on enrollments in the trial of the company’s cancer drug Inclusig, sending stock prices tumbling in unprecedented fashion. Shares dropped 66% to $5.83 which would represent the biggest drop in price since Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) […]